Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
Authors
Møller, PEvans, D Gareth R
Haites, N
Vasen, H
Reis, Marta M
Anderson, E
Apold, J
Hodgson, S
Eccles, D
Olsson, H
Stoppa-Lyonnet, D
Chang-Claude, J
Morrison, P J
Bevilacqua, G
Heimdal, K
Maehle, Lovise
Lalloo, Fiona
Gregory, H
Preece, P
Borg, A
Nevin, N C
Caligo, M
Steel, C M
Affiliation
Unit of Medical Genetics, Norwegian Radium Hospital, Oslo, Norway. pmoller@ulrik.uio.noIssue Date
1999-10
Metadata
Show full item recordCitation
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. 1999, 15 (1-3):207-11 Dis. MarkersJournal
Disease markersPubMed ID
10595280Type
ArticleLanguage
enISSN
0278-0240Collections
Related articles
- Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
- Authors: Pasini B, Pierotti MA
- Issue date: 1999 Oct
- Molecular cancer genetics in eastern and central Europe.
- Authors: Olah E
- Issue date: 1999 Oct
- Breast cancer genetics. Implications of clinical practice.
- Authors: Olufunmilayo I, Olopade MD, Fackenthal JD
- Issue date: 2000 Jun
- Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
- Authors: Chang-Claude J, Becher H, Caligo M, Eccles D, Evans G, Haites N, Hodgson S, Møller P, Weber BH, Stoppa-Lyonnet D
- Issue date: 1999 Oct
- The future of DNA diagnostics.
- Authors: Critchfield GC
- Issue date: 1999 Oct
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)